News

The first participant has entered ASCENT, a clinical study into the safety and tolerability of Liquidia’s Yutrepia, an inhaled dry powder formulation of treprostinil that is under regulatory review for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The open-label study (NCT06129240) seeks to enroll an estimated…

While non-oral treatments for pulmonary arterial hypertension (PAH) can help ease symptoms, they can also make for poorer quality of life as they add new day-to-day challenges that go beyond those posed by the disease itself, a study found. The study, “Patients’ perspectives on the challenges associated with…

People with pulmonary arterial hypertension (PAH) related to use of methamphetamine — a potent stimulant only legally available by prescription — tend to have worse heart health and poorer exercise capacity compared with patients with other forms of PAH. That’s according to a new study, “Methamphetamine-associated…

Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…

Atrial fibrillation or AF — a heart condition marked by an irregular heartbeat — is associated with longer hospital stays, higher inpatient mortality, and greater hospitalization costs in patients with pulmonary hypertension (PH), according to a new large-scale study. The findings indicate that this heart condition, common in people…

While about a quarter of pulmonary arterial hypertension (PAH) patients treated with the investigational therapy sotatercept tested positive for antibodies against it, the antibodies didn’t influence the therapy’s safety or effectiveness, according to a clinical trial analysis. The study, “The impact of immunogenicity on the pharmacokinetics,…

Delays beyond one year in the diagnosis of pulmonary arterial hypertension (PAH) lead to more hospitalizations, and this translates into higher healthcare costs per patient each month in the U.S., a real-world study found. Indeed, such extra costs per month were estimated at nearly $4,000 per patient after 12…

In people with pulmonary arterial hypertension (PAH), treatment with the novel cell therapy CAP-1002 was safe and showed encouraging efficacy, according to the results of a Phase 1a/b clinical trial. In particular, exploratory efficacy measures supported the potential of CAP-1002 in improving cardiopulmonary function, including exercise capacity, in PAH…

An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with interstitial lung disease — has dosed its first patient, the company announced. The goal for the investigational device is to provide patients…

INOmax EVOLV DS, a device to deliver nitric oxide gas by inhalation to newborns with pulmonary hypertension (PH), is expected to be available in hospitals in the U.S. in the first half of 2024. The U.S. Food and Drug Administration (FDA) has cleared the next-generation device, developed by…

Raymond Benza, MD, has been selected to be director of pulmonary hypertension (PH) for the Mount Sinai Health System, In this newly created position, Benza will seek to advance and standardize care for PH patients and further develop research in the progressive disorder that is associated with high blood…

Babies with persistent pulmonary hypertension of the newborn (PPHN) started quickly on treatment with prostaglandin E1 (PGE1) — which lowers blood pressure by allowing blood vessels to relax and open up — show a better working heart and a lesser need of extra oxygen, a study reports. “Importantly, the…